Samrat, S.K.; Xu, J.; Li, Z.; Zhou, J.; Li, H. Antiviral Agents against Flavivirus Protease: Prospect and Future Direction. Pathogens2022, 11, 293.
Samrat, S.K.; Xu, J.; Li, Z.; Zhou, J.; Li, H. Antiviral Agents against Flavivirus Protease: Prospect and Future Direction. Pathogens 2022, 11, 293.
Samrat, S.K.; Xu, J.; Li, Z.; Zhou, J.; Li, H. Antiviral Agents against Flavivirus Protease: Prospect and Future Direction. Pathogens2022, 11, 293.
Samrat, S.K.; Xu, J.; Li, Z.; Zhou, J.; Li, H. Antiviral Agents against Flavivirus Protease: Prospect and Future Direction. Pathogens 2022, 11, 293.
Abstract
Flaviviruses cause a significant amount of mortality and morbidity, especially in the area where they are endemic. A recent example is the outbreak of Zika virus though out the world. Development of antiviral drugs against different viral targets is as important as development of vaccine. During viral replication, the flavivirus genome is translated as a single polyprotein precursor, which must be cleaved into individual proteins by a complex of the viral protease, NS3, and its cofactor, NS2B. Flavivirus protease is the most attractive target for development of therapeutic antivirals because it is essential for processing of viral polyprotein precursor and generation of functional viral proteins. In this review, we have summarized recent development in drug discovery targeting NS3-NS2B protease of flaviviruses, especially Zika, dengue and West Nile virus.
Keywords
Flavivirus; NS2B-NS3; ZIKA Virus; Dengue Virus; West Nile Virus; Inhibitors
Subject
Biology and Life Sciences, Virology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
